Protocol Ledger

NCT03398135 · Phase III · ACTIVE NOT RECRUITING

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

Interventional Phase III clinical trial protocol NCT03398135 sponsored by AbbVie in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-08-28 Enrollment: 1,242 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03398135
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,242 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03398135
Protocol FieldVerified Registry Value
NCT IdentifierNCT03398135
Consolidated Lead SponsorAbbVie
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment1,242 participants (ACTUAL)
Registered Start Date2018-08-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI